Department of Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, USA.
Division of Hematology, Department of Medicine, University of Miami and Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave (D8-4), Miami, FL, 33136, USA.
Ann Hematol. 2024 Nov;103(11):4581-4588. doi: 10.1007/s00277-024-05997-1. Epub 2024 Sep 17.
Mantle cell lymphoma (MCL) is frequently diagnosed at advanced stages and is characterized by multiple extranodal sites of disease, most notably the bone marrow, peripheral blood, and gastrointestinal tract. Historically the prognosis of mantle cell lymphoma has been poor with median survival of four to five years. With new treatment regimens, however, patients have been able to achieve prolonged remissions and require special attention while being evaluated for relapse. This report describes four patients treated for stage IV mantle cell lymphoma at the University of Miami who developed soft tissue relapse presenting as non-tender large masses of the extremities, including one patient who presented without associated nodal involvement. Average time to soft tissue relapse was 99 months (range: 28-240) following initial diagnosis. Providers who care for patients with mantle cell lymphoma should be aware of soft tissue lesions as a presentation of mantle cell lymphoma that merits evaluation for disease relapse.
套细胞淋巴瘤(MCL)常被诊断为晚期,其特征是存在多个结外疾病部位,最常见的是骨髓、外周血和胃肠道。从历史上看,套细胞淋巴瘤的预后一直很差,中位生存期为四到五年。然而,随着新的治疗方案的出现,患者已经能够实现长期缓解,并且在评估复发时需要特别注意。本报告描述了在迈阿密大学接受治疗的四例 IV 期套细胞淋巴瘤患者,这些患者出现了软组织复发,表现为四肢无痛性巨大肿块,其中一例患者无相关淋巴结受累。首次诊断后,软组织复发的平均时间为 99 个月(范围:28-240)。治疗套细胞淋巴瘤的医生应该意识到软组织病变是套细胞淋巴瘤的一种表现,需要评估疾病是否复发。